Publications

Any
    Any

      5596 Results

      SWOG S2210: A PHASE II STUDY OF NEOADJUVANT CARBOPLATIN FOR LOCALIZED, HIGH RISK PROSTATE CANCER WITH GERMLINE BRCA1/2 MUTATIONS

      Authors
      H Cheng;S Callis;D Lin;E Yu;T Dorff;A Kase;C Tangen;D Petrylak;S Lerner
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      S2210

      AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIBC) vs Observation

      Authors
      A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;E Levine;Z Reichert;J Kim;M Bilen;Y Wen;O Hahn;S Halabi;G Perez;M Morris;J Rosenberg
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral; J Clin Oncol 42, 2024 (suppl 4; abstr LBA531)
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      CTSU/A031501

      Bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient level analysis of SWOG 1216 trial

      Authors
      G Gebrael;M Plets;Y Jo;U Swami;C Chehade;A Narang;S Gupta;N Sayegh;C Tangen;M Hussain;T Dorff;P Lara;S Lerner;I Thompson;N Agarwal
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      S1216

      Urinary comprehensive genomic profile correlates with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605

      Authors
      M St-Laurent;M Plets;P Black;P Singh;D McConkey;MS Lucia;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;C Tangen;I Thompson;J Meeks;V Caruso;K Philllips;V Bicocca;T Levin;S Lerner
      Journal / Conference
      ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
      Year
      2024
      Research Committee(s)
      Genitourinary
      Study Number(s)
      S1605

      A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers

      Authors
      AP Algazi;J Moon;C Lao;B Chmielowski;K Kendra;K Lewis;R Gonzalez;K Kim;JE Godwin;B Curti;M Latkovic-Taber;S Lomeli;B Gufford;P Scumpia;R Lo;M Othus;A Ribas
      Journal / Conference
      Cancer May 15;130(10):1784-1796
      Year
      2024
      Research Committee(s)
      Melanoma
      PMID
      PMID38261444
      Study Number(s)
      S1221

      Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial

      Authors
      E Parra;D Duose;J Zhang;M Redman;R Lazcano Segura;M Marques-Puibelli;C Fernandez;B Zhang;J Lindsay;R Moravec;K Kannan;R Luthra;G Al-atrash;R Herbst;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang;C Haymaker;G Manyam;J Zhang;X Song;F Rojas;L Taing;A Jhaveri;J Geisberg;J Altreuter;F Michor;D Van Nostrand;J Provencher;J Yu;E Cerami;H Huang;H Xie;M Patel;K Nie;J Harris;K Argueta;R Biswas;S Kim-Schulze;K Kelly;S Gnjatic
      Journal / Conference
      Clinical Cancer Research Apr 15;30(8):1655-1668
      Year
      2024
      Research Committee(s)
      Lung
      PMID
      PMID38277235
      PMC
      PMC11016892
      Study Number(s)
      S1400I

      Clinical Evaluation of Complete Remission (CR) with Partial Hematologic Recovery (CRh) in Acute Myeloid Leukemia: A Report of 7,235 Patients from Seven Cohorts Running head: Survival following CRh in AML

      Authors
      J Appelbaum;A Wei;S Mandrekar;I Tiong;C Chua;T Teh;C Fong;S Ting;D Weber;A Benner;H Hill;M Saadati;J Yin;R Stone;G Garcia-Manero;H Erba;G Yy;G Marcucci;R Larson;A Thomas;S Freeman;N Marquez Almuina;K Dohner;I Thomas;N Russel;H Dohner;M Othus;E Estey;R Walter
      Journal / Conference
      Leukemia Feb;38(2):389-392
      Year
      2024
      Research Committee(s)
      Leukemia
      PMID
      PMID38263433

      CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma

      Authors
      G Abou-Alfa;S Geyer;A Nixon;F Innocenti;Q Shi;S Jacobson;I El Dika;A Yaqubie;J Lopez;B Hwang;A El-Khoueiry;Y Tang;Y Wen;L Schwartz;M Bertagnolli;J Meyerhardt;E O'Reilly;A Venook
      Journal / Conference
      Cancer Research Communications Mar 7;4(3):682-690
      Year
      2024
      Research Committee(s)
      Gastrointestinal
      PMID
      PMID38363156
      PMC
      PMC10919207
      Study Number(s)
      CTSU/C80802

      Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

      Authors
      A Lo;A Liu;Q Liu;Y Yasui;S Catellino;K Kelly;A Hererra;JW Friedberg;D Friedman;C Schwartz;Q Pei;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson
      Journal / Conference
      JAMA Network Open Jan 2;7(1):e2351062
      Year
      2024
      Research Committee(s)
      Lymphoma
      PMID
      PMID38241048
      PMC
      PMC10799264
      Study Number(s)
      S1826

      Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

      Authors
      H Arai;Y Yang;J Millstein;T Denda;F Ou;F Innocenti;H Takeda;Y Kubota;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;P Jayachandran;S Algaze;S Soni;W Zhang;W Zhang;R Goldberg;M Hall;A Scott;J Hwang;E Lou;B Weinberg;J Marshall;S Goel;J Xiu;M Korn;A Venook;Y Sunakawa;H-J Lenz
      Journal / Conference
      European Journal of Cancer Apr:201:113914
      Year
      2024
      Research Committee(s)
      Gastrointestinal
      PMID
      PMID: 38359495
      Study Number(s)
      CTSU/C80405